newsfilter
← Latest News
PR Newswire·

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

CRDL
  • Cardiol Therapeutics achieved its original 110-patient enrollment target for the MAVERIC Phase III trial ahead of the end-of-September 2026 guidance.
  • The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to ensure sufficient event counts for a robust assessment of CardiolRx™.
  • A blinded review revealed fewer-than-expected pericarditis recurrences, which the company views as encouraging data.
  • Topline results for the expanded trial are now anticipated in mid-2027, a delay from the previous Q1 2027 guidance.
  • Existing capital is expected to fund the completion of the MAVERIC study, with a cash runway extending into Q1 2028.
  • The trial's primary efficacy endpoint will assess the time to a first new episode of pericarditis recurrence.
  • A secondary endpoint will evaluate the proportion of patients free from a new episode of recurrent pericarditis at the end of the study.